A trio of amyloid-targeted Alzheimer's drugs will soon see key results, but an analyst predicts only 50-50 odds for one
Piggybacking off of Biogen’s controversial accelerated approval for Aduhelm, new pivotal data are coming soon from three other amyloid-targeted Alzheimer’s drugs from Roche, Eli Lilly and Biogen again.
Analysts at Stifel Biotechnology Equity Research are predicting in a new investor note this week that Lilly might have the best odds with its donanemab, although all three have questions that remain to be answered before they can win an approval, even if it’s an accelerated nod.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
